Skip to content

Investigating the effect of Duloxetine in improving complications caused by vincristine treatment in children with cancer

study of effectiveness of Duloxetine in improving symptoms of chemotherapy induced polyneuropathy by vincristine in children with cancer in Mofid Hospital in 1403.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230827059268N1
Enrollment
56
Registered
2024-06-23
Start date
2024-06-21
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polyneuropathy. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: 28 patients with polyneuropathy caused by vincristine who will be treated with 20 mg Duloxetine in the first week and after one week the dose will be increased to 4

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients with an age range between 5 and 18 years patients with Cancer who have been treated with vincristine Patients who have complications and clinical symptoms of CIPN according to the clinical diagnosis of the relevant oncologist.

Exclusion criteria

Exclusion criteria: present other underlying polyneuropathies

Design outcomes

Primary

MeasureTime frame
Electrodiagnosis test findings in the investigation of polyneuropathy. Timepoint: At the time of visit (before the start of the intervention), 2 months after receiving the intervention. Method of measurement: EMG AND NCS device.;Findings from the questionnaire : Pediatric modified total neuropathy score. Timepoint: At the time of visit (before the start of the intervention), 2 months after receiving the intervention. Method of measurement: Pediatric modified total neuropathy score questionnaire.

Secondary

MeasureTime frame
Drug side effects. Timepoint: At the beginning of the study, before the start of the intervention and 14 days and 30 days after the intervention, in person and in all stages, in the form of free telecommunication between the patient and the relevant doctor. Method of measurement: Questioning the patient and clinical examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh raeisi mohammadi

Shahid Beheshti University of Medical Sciences

Dr.atefeh1374@gmail.com+98 21 7763 2493

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026